Plethico Pharmaceuticals Ltd.

BSE: 532739
₹7.94
▼ -0.41 (-4.91%)
June 13, 2016 · BSE · bse_bhavcopy
Quality
—/100
Data unavailable
Valuation
—/100
Data unavailable
Momentum
43/100
Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
Data unavailable.
PE (TTM)
Data unavailable.
Price to Book
Data unavailable.
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
-16.1
Relative return vs Sector, qtr %
Data unavailable.
Free Cash Flow
Data unavailable.
EPS Growth (YoY)
Data unavailable.
Net Profit Growth (TTM)
Data unavailable.
Operating Revenue Growth (TTM)
Data unavailable.
Profit Growth (YoY)
Data unavailable.
Revenue Growth (YoY)
Data unavailable.
Current Ratio
Data unavailable (needs a filed half-yearly balance sheet).
Debt to Equity
Data unavailable (needs a filed half-yearly balance sheet).
Interest Coverage
Data unavailable.
Net Margin
Data unavailable.
Operating Margin (EBIT)
Data unavailable.
Operating Margin (TTM)
Data unavailable.
Return on Assets
Data unavailable.
Return on Capital Employed
Data unavailable (needs a filed half-yearly balance sheet).
Return on Equity
Data unavailable (needs a filed half-yearly balance sheet).

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Value and momentum

0 of 4 met
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-4.9%
Low 7.9400 · High 8.3000
1W return
-4.9%
Low 7.9400 · High 8.3000
1M return
-5.6%
Low 7.5800 · High 8.7000
52W return
-70.2%
Low 7.5800 · High 36.9000
Lifetime High ₹507.3000 (Jan. 7, 2008)
Lifetime Low ₹7.9400 (June 13, 2016)

Full price history and technicals →

EMA & SMA

Bullish0
Bearish6
5D
8.2
10D
8.6
20D
9.6
50D
13.0
100D
17.4
200D
24.9

Delivery and volume

Day avg. delivery
100.0%
Week avg. delivery
100.0%
Month avg. delivery
100.0%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

8.06
Pivot
First resistance8.18
Second resistance8.42
Third resistance8.54
First support7.82
Second support7.70
Third support7.46
Day RSI27.8
Day MFI39.0
Day MACD-1.58
Day MACD signal-1.70

Beta

1M—
3M—
1Y1.07
3Y0.71

Price change analysis

↓ -5.6%
Over 1 Month
LowHigh
7.588.70
↓ -25.4%
Over 3 Months
LowHigh
7.5811.17
↓ -33.7%
Over 6 Months
LowHigh
7.5815.00
↓ -70.2%
Over 1 Year
LowHigh
7.5836.90
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →

Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).

Data unavailable.

Shareholding pattern / Ownership

Shareholding summary

Jun 2016
  • Promoter57.75%
  • FII/FPI2.70%

Largest holders

Data unavailable.

Historical promoter holding

Historical fii holding

All shareholding details →

DateClientDealActionQuantityPriceExchange
26 Nov 2015 SICOM LIMITED Bulk Sell 293,000 10.7200 BSE

All bulk and block deals →

Ex-dateSubjectPer share (₹)Record date
22 Sep 2011 Dividend-Rs.2.50 Per Share 2.5000 —
24 Jun 2010 Dividend-Rs.2.50 Per Share 2.5000 —
18 Jun 2009 Agm/Dividend-25% — —
20 Jun 2008 Agm/Dividend - 25% — —
23 Mar 2007 Agm/Dividend-25% — —

Corporate Actions

Full history (8 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
15 Dec 2014OTHERAnnual General Meeting
21 Jun 2013OTHERAnnual General Meeting
25 Jun 2012OTHERAnnual General Meeting

All corporate actions →

Corporate Announcements

All 56 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
18 May 2018 Delisting ��Members of the Exchange are hereby notified that in terms of Regulation 22(6) of the Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009, Section 21A of the Securities Contract (Regulations) Act, 1956, Rule 21(2) b of Securities Contract (Regulations) Rules, 1957 , it has been decided to delist (withdraw the admission to dealings in) equity shares of the Plethico Pharmaceuticals Limited w.e.f. May 30, 2018 as per Chapter V of SEBI (Delisting of Equity Shares) Regulations, 2009.
28 Feb 2018 Public Notice - Compulsory Delisting Members of the Exchange are hereby informed that the Exchange on February 28, 2018 has issued public notice in the newspaper for�� proposed compulsory delisting of equity shares of the company, in term of Regulation 22 (3) of SEBI (Delisting of Equity shares) Regulation, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/common/CorporateAnnouncements).
10 May 2016 Resignation Plethico Pharmaceuticals Limited has informed the Exchange that the Company has received a resignation letter from the Director Ms Meena Matani.
18 Apr 2016 Disc. under Reg.30 of SEBI (SAST) Reg.2011 Shashikant A. Patel has submitted to the Exchange vide letter dated April 07, 2016 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.
28 Mar 2016 Updates Plethico Pharmaceuticals Limited has informed the Exchange that With a view to address the delay in repayment of principal and interest on fixed deposits, service banking facilities, pay statutory dues and sustain its business operations, the Company has opted to adopt contract manufacturing model for its operation.
15 Mar 2016 Financial Result Updates Plethico Pharmaceuticals Limited has submitted to the Exchange the standalone & consolidated financial results along with the Auditors Report for the period ended March 31, 2015.
8 Mar 2016 Trading Window Plethico Pharmaceuticals Limited has informed the Exchange that the Trading Window for the equity shares of the Company shall remain closed from March 9, 2016 to March 16, 2016 (both days inclusive) . lnter-alia to consider and approve the audited financial results for the quarter and year ended March 31, 2015.Accordingly, all the insiders and Designated Persons (including directors and employees) and others who have come in to the receipt of any insider information are hereby directed not to deal in shares of he Company during the period of closure of Trading Window as stated above.
5 Feb 2016 Change in Director(s) Plethico Pharmaceuticals Limited has informed the Exchange regarding appointment and resignation of Whole Time Director and Reconstitution of the Committee.
4 Feb 2016 Updates Plethico Pharmaceuticals Limited has informed the Exchange regarding the details of authorized Key Managerial Personnel for the purpose of determining materiality of an event or information and for the purpose of making disclosures to the Stock Exchanges.
14 Jan 2016 Outcome of Board Meeting Plethico Pharmaceuticals Limited has informed the Exchange about the Intimation of Appointment of Director and Rename and Reconstitution of the Committee

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

Data unavailable.

Weaknesses

Data unavailable.

Opportunities

  • RSI in oversold territory (27.8) -- a technical rebound zone

Threats

  • Down 70.2% over the past year

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Plethico Pharmaceuticals Ltd.

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.